Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 1998
Business Overview: Incyte operates two divisions: Incyte General (established, profitable database and genomic services) and Incyte Genetics (early-stage, high-investment SNP discovery). The company designs and markets genomic information-based tools, including database products, software, reagents, and microarray services.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 1998 | 9 Months Ended Sep 30, 1998 | 9 Months Ended Sep 30, 1997 |
|---|---|---|---|
| Revenues | $34,692 | $98,164 | $62,649 |
| Net Income (Loss) | $(6,786) | $1,987 | $3,832 |
| Diluted EPS | $(0.25) | $0.07 | $0.15 |
| Operating Cash Flow (9mo) | $41,978 | ||
| Cash & Equivalents (Sep 30, 1998) | $45,350 | ||
| Total Assets (Sep 30, 1998) | $232,959 | ||
| Accumulated Deficit | $(29,886) |
Key Expenses (9 Months 1998): Research and Development ($69.6M); Selling, General & Administrative ($17.2M); Charge for purchase of in-process R&D ($11.0M); Acquisition-related charges ($1.2M).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 50% year-over-year for the nine-month period ($98.2M vs. $62.6M), driven by new and expanded database collaboration agreements.
- Profitability Impact: While the nine-month period showed a net income of $2.0M, the third quarter resulted in a net loss of $6.8M. This reversal was primarily due to a $11.0M non-cash charge for in-process research and development (IPR&D) related to the Hexagen acquisition.
- Acquisitions:
- Hexagen Limited: Acquired in September 1998 for approx. $29.9M (stock and cash). $11.0M was expensed as IPR&D.
- Synteni, Inc.: Acquired in January 1998 (pooling-of-interests). Financials for 1997 have been restated to include Synteni.
- Expense Increases: R&D expenses rose 36% and SG&A expenses rose 74% compared to the prior nine-month period, reflecting investments in bioinformatics, microarray capacity, and legal defense costs.
Guidance, Outlook, and Risks
- Future Losses: Management expects to report consolidated net losses for fiscal 1999 and possibly 2000 due to significant investments required for the Incyte Genetics division (estimated $100M-$150M over the next few years).
- Capital Structure Proposal: The Board recommended a proposal to split the company into two series of common stock (Incyte General and Incyte Genetics) to reflect the distinct performance of each division.
- Stockholder Rights Plan: Adopted a "poison pill" plan on September 25, 1998, triggering at 15% ownership to deter hostile takeovers.
- Litigation Risk: Affymetrix, Inc. filed two lawsuits (January and September 1998) alleging patent infringement regarding microarray technology. Incyte intends to defend vigorously, but the litigation is expected to result in substantial expenses and management distraction. There is no assurance of a favorable outcome or that licenses will be available on acceptable terms.
- Year 2000 Compliance: Estimated cost to achieve compliance is $1.0M-$1.5M. Risks include potential system failures or disruptions from third-party vendors.
Investor Verification Checklist
- Hexagen Integration: Verify the timeline and success of integrating Hexagen's SNP discovery technology and the realization of the $11.0M IPR&D charge value.
- Litigation Exposure: Monitor the status of the Affymetrix lawsuits for potential injunctions, damages, or settlement costs that could materially impact operations.
- Incyte Genetics Funding: Assess the company's ability to raise the projected $100M-$150M required for Incyte Genetics, including the potential dilution from future equity offerings.
- Revenue Concentration: Review the dependency on database collaboration agreements and the risk of non-renewal or early termination by pharmaceutical partners.
- Stock Split Proposal: Confirm stockholder approval status for the dual-class stock structure, which could alter the investment thesis for the two distinct business lines.